{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Johnson SR"],"funding":["NHLBI NIH HHS"],"pagination":["1182-1200"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12646471"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["76(8)"],"pubmed_abstract":["<h4>Objective</h4>We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs).<h4>Methods</h4>We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations.<h4>Results</h4>Thirty-five recommendations were generated (including two strong recommendations) for first-line SARD-ILD treatment, treatment of SARD-ILD progression despite first-line ILD therapy, and treatment of rapidly"],"journal":["Arthritis & rheumatology (Hoboken, N.J.)"],"pubmed_title":["2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases."],"pmcid":["PMC12646471"],"funding_grant_id":["R01 HL169166","R01 HL166290"],"pubmed_authors":["McMahan ZH","Natalini JG","Guyatt G","Solomon JJ","McDermott GC","Lee JS","Saygin D","Agarwal SK","Bolster MB","Warrier A","Singh N","Oldham JM","Hallowell R","Domsic RT","Vaseer S","Bemiss B","Corwin DS","Dematte D'Amico JE","Makol A","Merck SJ","Hinze AM","Summer R","Jiwrajka N","Lakin KS","Chami HA","Shapiro L","Antin-Ozerkis D","Chung JH","Dellaripa PF","Frech TM","Kim JS","Doyle TJ","Kanne JP","Chowdhary V","Hinchcliff M","Nesbitt K","Lim SY","Mirza RD","Gibbons FK","Johnson SR","Aggarwal R","Joerns EK","Khanna D","Turner A","Bernstein EJ","Scholand MB","Sparks JA","Uhl S","Assassi S","Johnson C","Buckley L","George MD","Varga J","Turgunbaev M","Allen A","Falardeau CM","Matson S","Injean PA","Danoff SK","Sharkey CD","Ivlev I"],"additional_accession":[]},"is_claimable":false,"name":"2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.","description":"<h4>Objective</h4>We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs).<h4>Methods</h4>We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations.<h4>Results</h4>Thirty-five recommendations were generated (including two strong recommendations) for first-line SARD-ILD treatment, treatment of SARD-ILD progression despite first-line ILD therapy, and treatment of rapidly","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-06-05T19:03:55.825Z","creation":"2026-05-20T03:14:52.605Z"},"accession":"S-EPMC12646471","cross_references":{"pubmed":["38978310"],"doi":["10.1002/art.42861"]}}